Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV antibody seroprevalence study in PKP2-associated ARVC
NL-OMON56804Withdrawn
- Sponsor
- Tenaya Therapeutics
- Start
- Jan 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial in arrhythmogenic right ventricular cardiomyopathy (ARVC), sponsored by Tenaya Therapeutics. Primary endpoint: AAV antibody titers. Planned start Jan 2024; status: withdrawn.
02
Conditions
arrhythmogenic right ventricular cardiomyopathy (ARVC)
Beyond the preview
Go deeper on NL-OMON56804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56804.